BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Multiple myeloma clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for multiple myeloma: 297 (112 sponsors; 34 newly posted in the last 180 days, 9 stopped in the last 180 days; 8 new-entrant sponsors). Momentum score 14.6, rank 45 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 6, Phase 1 82, Phase 2 96, Phase 3 71, Phase 4 5, N/A 37.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Janssen Research & Development, LLC33P1 10, P3 12, P2 10, P4 123
GlaxoSmithKline20P2 9, P3 7, P1 430
AbbVie ABBV17P3 5, P1 7, P2 511
Pfizer PFE12P3 4, NA 4, P1 2, P4 222
Regeneron Pharmaceuticals REGN12P4 1, P2 7, P1 1, P3 310
Sanofi SNY8P2 4, P3 3, P1 102
AstraZeneca AZN7P1 1, P2 3, P3 330
Celgene6P2 3, P3 302
Qilu Pharmaceutical Co., Ltd.6P2 1, P3 3, P1 210
Kite, A Gilead Company5P2 1, P1 1, P3 321
Bristol-Myers Squibb BMY8NA 4, P3 2, P2 1, P1 101
Keymed Biosciences Co.Ltd3P3 2, P2 111
Alexion Pharmaceuticals, Inc.2P3 200
Hoffmann-La Roche5P2 3, P1 1, P3 111
Nanjing IASO Biotechnology Co., Ltd.5P1 2, P2 1, NA 1, P3 100
Genrix (Shanghai) Biopharmaceutical Co., Ltd.4P3 1, P2 301
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company4P2 1, P3 1, P1 200
Takeda TAK4NA 3, P3 102
CellCentric Ltd.3P2 2, P3 111
Hangzhou Sumgen Biotech Co., Ltd.3P1 1, P2 1, P3 101
Innovent Biologics (Suzhou) Co. Ltd.3P2 2, P3 121
Biocad2P2 1, P3 110
Shandong New Time Pharmaceutical Co., LTD2P3 1, P2 100
Shanghai Henlius Biotech2P3 1, P1 100
BioLineRx, Ltd. BLRX1P3 100

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-30 est.P1/P2CelgeneNCT03989414 A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments inMultiple Myelomaactive not recruiting424
2026-11-30 est.P1/P2OriCell Therapeutics Co., Ltd.NCT06182696 OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMMRelapsed and/or Refractory Multiple Myelomarecruiting83
2026-12 est.P1/P2Keymed Biosciences Co.LtdNCT05299424 A Study of CM336 in Patients With Relapsed or Refractory Multiple MyelomaMultiple Myelomarecruiting48
2026-12 est.P2Kite, A Gilead CompanyNCT05396885 Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)Multiple Myelomaactive not recruiting136
2026-12-31 est.P1/P2Chongqing Precision Biotech Co., LtdNCT04271644 BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell DiseaseMultiple Myeloma; Neoplasm, Plasma Cell; Multiple Myeloma in Relapserecruiting80
2026-12-31 est.P1/P2Chongqing Precision Biotech Co., LtdNCT04776330 a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell DiseaseMultiple Myeloma; Neoplasm, Plasma Cell; Multiple Myeloma in Relapserecruiting80
2026-12-31 est.P2GeoVax, Inc. GOVXNCT04977024 SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood CancerCOVID-19 Infection; Hematopoietic and Lymphoid System Neoplasm; Leukemia; Lymphoma; Plasma Cell Myelactive not recruiting63
2026-12-31 est.P1/P2Zhejiang ACEA Pharmaceutical Co. Ltd.NCT05565807 Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple MyelomaRelapsed or Refractory Multiple Myelomarecruiting84
2026-12-31 est.P2Innovent Biologics (Suzhou) Co. Ltd.NCT07764861 A Open-Label Phase in Participants With Multiple MyelomaMultiple Myelomanot yet recruiting120
2027-01-10 est.P3CelgeneNCT05519085 A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Relapsed or Refractory Multiple Myelomarecruiting810

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11 est.P1/P2BeOne Medicines ONCNCT04973605 A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, anRelapsed/Refractory Multiple Myelomarecruiting246
2026-10-31 est.P1/P2Innovent Biologics (Suzhou) Co. Ltd.NCT06083207 A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple MyelomaMultiple Myelomarecruiting116
2026-10-12 est.P1/P2Bristol-Myers Squibb BMYNCT05372354 A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or RefractMultiple Myelomarecruiting260
2026-09-28 est.P3Bristol-Myers Squibb BMYNCT05552976 A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With RelapsRelapsed or Refractory Multiple Myelomaactive not recruiting606
2026-09-11P3Guangzhou Gloria Biosciences Co., Ltd.NCT06514508 Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma PatientsMultiple Myelomarecruiting60
2026-08-26P3Pfizer PFENCT06152575 MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other TreatmentMultiple Myelomarecruiting492
2026-08 est.P3AbbVie ABBVNCT03539744 A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in ParticiMultiple Myelomaactive not recruiting265
2026-07-31 est.P1/P2Genrix (Shanghai) Biopharmaceutical Co., Ltd.NCT07090954 A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple MyelomaMultiple Myelomanot yet recruiting32
2026-07-31P2Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyNCT06297226 Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple MyelomaMultiple Myelomarecruiting230
2026-06-22 est.P2Cellectar Biosciences, Inc. CLRBNCT02952508 Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in WaldenstromWaldenstrom Macroglobulinemia; Multiple Myeloma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymactive not recruiting120
2026-06-20 est.P1/P2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT05055791 A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic MalignanciesAcute Myeloid Leukemia; Lymphoma; Multiple Myelomaunknown312
2026-05-31 est.P2US Oncology ResearchNCT04782687 Study of Selinexor Plus DRd for Newly Diagnosed Multiple MyelomaMultiple Myeloma; Myeloma Multiple; Kahler Disease; Myeloma, Plasma Cell; Myeloma-Multiple; Myelomatactive not recruiting73

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "multiple myeloma"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.